1093956-67-2

Upstream product

• 1774-47-6 trimethylsulfoxonium iodide 
• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 

Downstream Products

• 1093956-79-6 1,1-Dimethylethyl 5-fluoro-1'-[2-hydroxy-2-(1-{[(phenylmethyl)oxy]carbonyl}-4-piperidinyl)ethyl]spiro[indole-3,4'-piperidine]-1(2H)-carboxylate 
• 1093957-02-8 benzyl 4-[(2S)-oxiran-2-yl]piperidine-1-carboxylate 
• 1119270-41-5 1-{1-[(2E)-3-(4-chlorophenyl)-2-propenoyl]-4-piperidinyl}-2-(1'H-spiro[indene-1,4'-piperidin]-1'-yl)ethanol 

Relevant academic research and scientific papers

N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES

Provided herein are small molecule compounds of the following formula (I): or a stereoisomer, tautomer, solvate, ester or pharmaceutically acceptable salt thereof, wherein A, B, C, Li, L 2, Ri, R 2, R 3, R 4, R 5, w, x, y and z are as defined herein. Methods for treating diseases/ disorders by antagonizing muscarinic receptors, including specifically antagonizing muscarinic receptor 4 (M4), are also disclosed. Such diseases/disorders are e.g. neurological diseases/disorders such as e.g. Alzheimer's Disease, Lewy Body Dementia and the cognitive deficits associated with schizophrenia, Parkinson's Disease, drug induced Parkinsonism, dyskinesias, dystonia, chorea, levodopa induced dyskinesia, cerebral palsy, progressive supranuclear palsy, and Huntington's disease. Preferred compounds are e.g. N-[2-(l-benzylpiperidin-4-yl)ethyl]-4- (pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds wherein the pyrazine has been replaced by e.g. pyridazine, pyrimidine, pyridine or phenyl.

OXAZOLES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein R1-R7, X, Y, m, and n are as described herein. Compounds of the present invention are useful for the treatment of a variety of diseases associated with overexpression of the CCR2 receptor.

INDOLINYL-, BENZOFURANYL-, AND BENZOTHIENYL- AMIDES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein R1-R5, X, Y, m, and n are as defined herein. Compounds of the present invention are useful for the treatment of a vari

SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof; where R1-R5, Y, m, n, and p are defined herein. Compounds and compositions of the present invention are useful the treatment of atherosclerosis.

PIPERIDINYLHYDROXYETHYLPIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of the formula (I), or a pharmaceutically acceptable salt thereof, wherein R1-R8 and X, m, and n are defined. Compounds and compositions of the present invention are useful the treatment of atherosclerosis.

SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of the following formula: where R1-R6, R10, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases